EGFR驱动肺癌生长与治疗反应的遗传决定因素体内研究
该研究在EGFR驱动、Trp53缺陷的小鼠肺腺癌模型中失活10个推定抑癌基因,发现Apc、Rb1或Rbm10失活强烈促进肿瘤生长,而Lkb1或Setd2失活反而减少EGFR驱动肿瘤生长。KEAP1失活降低肿瘤对奥希替尼的敏感性,KEAP1通路突变与患者酪氨酸激酶抑制剂治疗时间缩短相关。
要点
- Apc、Rb1或Rbm10失活强烈促进EGFR驱动肺腺癌生长。
- Lkb1或Setd2失活减少EGFR驱动肿瘤生长,与KRAS驱动模型相反。
- KEAP1失活降低EGFR驱动肿瘤对奥希替尼的敏感性。
核心结论
- 遗传改变对肿瘤生长的影响因致癌背景而异,且治疗会改变适应度景观。
- KEAP1失活降低EGFR突变肿瘤对酪氨酸激酶抑制剂的敏感性。
研究设计与样本
- 在EGFR驱动Trp53缺陷小鼠肺腺癌模型中定量失活10个推定抑癌基因的效应。
主要发现
- Apc、Rb1或Rbm10失活强烈促进肿瘤生长。
- Lkb1或Setd2失活减少EGFR驱动肿瘤生长。
- KEAP1失活降低EGFR驱动肿瘤对奥希替尼的敏感性。
- KEAP1通路基因突变与患者酪氨酸激酶抑制剂治疗时间减少相关。
关键数值与推荐
- 失活10个推定抑癌基因;Apc、Rb1或Rbm10失活强烈促进肿瘤生长。
- Lkb1或Setd2失活减少EGFR驱动肿瘤生长。
- KEAP1失活降低对奥希替尼的敏感性。
- KEAP1通路突变与患者酪氨酸激酶抑制剂治疗时间减少相关。
临床怎么用
- EGFR突变肺腺癌患者可关注KEAP1通路突变以评估酪氨酸激酶抑制剂敏感性。
- 抑癌基因共突变对EGFR靶向治疗的影响需结合具体基因背景解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In lung adenocarcinoma, oncogenic EGFR mutations co-occur with many tumor suppressor gene alterations; however, the extent to which these contribute to tumor growth and response to therapy in vivo remains largely unknown. By quantifying the effects of inactivating 10 putative tumor suppressor genes in a mouse model of EGFR-driven Trp53-deficient lung adenocarcinoma, we found that Apc, Rb1, or Rbm10 inactivation strongly promoted tumor growth. Unexpectedly, inactivation of Lkb1 or Setd2-the strongest drivers of growth in a KRAS-driven model-reduced EGFR-driven tumor growth. These results are consistent with mutational frequencies in human EGFR- and KRAS-driven lung adenocarcinomas. Furthermore, KEAP1 inactivation reduced the sensitivity of EGFR-driven tumors to the EGFR inhibitor osimertinib, and mutations in genes in the KEAP1 pathway were associated with decreased time on tyrosine kinase inhibitor treatment in patients. Our study highlights how the impact of genetic alterations differs across oncogenic contexts and that the fitness landscape shifts upon treatment. SIGNIFICANCE: By modeling complex genotypes in vivo, this study reveals key tumor suppressors that constrain the growth of EGFR-mutant tumors. Furthermore, we uncovered that KEAP1 inactivation reduces the sensitivity of these tumors to tyrosine kinase inhibitors. Thus, our approach identifies genotypes of biological and therapeutic importance in this disease.This article is highlighted in the In This Issue feature, p. 1601.
引用
- Foggetti G, Li C, Cai H, et al. Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo. Cancer Discov. 2021. PMID: 33707235. doi:10.1158/2159-8290.CD-20-1385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。